Eton Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
Rhea-AI Summary
Eton Pharmaceuticals, Inc. (Nasdaq: ETON) will report its first quarter 2022 financial results on May 12, 2022. A conference call and live audio webcast will occur at 4:30 p.m. ET, allowing management to discuss results and take live questions from participants. Investors can also submit questions via email. The live webcast is accessible on Eton's investor website, with an archived version available for 30 days post-event. Eton specializes in treatments for rare diseases and currently holds royalties from seven FDA-approved products, with three more awaiting FDA review.
Positive
- Eton owns or receives royalties from seven FDA-approved products.
- Three additional products have been submitted to the FDA.
Negative
- None.
News Market Reaction – ETON
In the trading session that priced this news, ETON gained 3.13%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DEER PARK, Ill., May 03, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2022 financial results on Thursday, May 12, 2022. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT).
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
The live webcast can be accessed on the investors section of Eton’s website at https://ir.etonpharma.com/. The conference call can be accessed by dialing 1-866-795-8473 (domestic) or 1-470-495-9161 (international) and refer to conference ID 9537298. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently owns or receives royalties from seven FDA-approved products, including ALKINDI SPRINKLE®, Carglumic Acid, Biorphen®, Alaway® Preservative Free, Rezipres®, Eprontia™, and cysteine injection and has three additional products that have been submitted to the FDA.
Investor Contact:
David Krempa
dkrempa@etonpharma.com
612-387-3740
